411
Views
7
CrossRef citations to date
0
Altmetric
Research Articles

Current Advancement in the Oxadiazole-Based Scaffolds as Anticancer Agents

, , , , , , & show all
Pages 4183-4215 | Received 19 May 2020, Accepted 29 Jan 2021, Published online: 18 Feb 2021
 

Abstract

Heterocyclic nucleus is vital in medicinal chemistry and has allured significant attention in chemotherapeutic domain. Oxadiazole, a five-membered nitrogen–oxygen-containing heterocyclic core has remarkable anticancer activity. Mechanism associated in defeating tumor corresponds with inhibiting various enzymes and growth factors. Considering the importance of oxadiazole and its derivatives in this panic issue worldwide, this review has discussed research carried out from last 7 years and also their future outlook in drug development as antineoplastic agents. The objective of this review is to emphasize on anticancer activity of 1,3,4-oxadiazole and 1,2,4-oxadiazole derivatives. The precised features and framework of each research topic is introduced for helping the readers in understanding the perspective of the context in better way.

Acknowledgements

Garima Kapoor, Parul Grover, Kandasamy Nagarajan and Shadab Ahmad are deeply indebted to the Director Dr. (Col.) A. Garg and Joint Director, Dr. Manoj Goel, KIET Group of Institutions for their inspiration and support. We also express gratitude to Dr. Jagannath Sahoo, Principal, KIET School of Pharmacy, for his motivation and guidance.

Disclosure statement

The authors declare no conflicts of interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.